New approach to prevent breast cancer by targeting a specific histamine receptor
Official title: Exploring new strategy for breast cancer immunoprevention by targeting histamine receptor H1
Funded at University of Tx Md Anderson Can Ctr · NIH-11035062 · Data updated 2026-11-12
This study is looking at how a type of allergy medicine called H1-antihistamines might help boost the immune system's ability to fight breast cancer, especially for patients who have already used these medications during their treatment.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | February 14, 2024 |
| Project end | January 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $189,338 |
| NIH project number | 5R21CA286318-02 |
| Project ID | NIH-11035062 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women at high risk for developing breast cancer, especially those with stage 0 or 1 breast cancer.
✕Less likely to help
Patients who have already been diagnosed with advanced breast cancer or those not at risk for developing the disease may not benefit from this research.
What this research studies
This research investigates a novel strategy for preventing breast cancer by focusing on the histamine receptor H1. It aims to understand how high levels of histamine and H1 receptor expression in tumors affect immune responses in breast cancer patients. The study will explore the potential of H1-antihistamines to enhance the effectiveness of immunotherapy by improving the activity of immune cells that fight tumors. Patients who have previously taken H1-antihistamines during immunotherapy may see improved outcomes, suggesting a promising avenue for breast cancer prevention.
Why it matters
Potential benefit: If successful, this research could lead to new prevention strategies for breast cancer, particularly for women at high risk.
How similar studies have gone: Previous studies have shown promising results with H1-antihistamines in improving outcomes for patients undergoing immunotherapy, indicating that this approach may be effective.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Xiao, Yi — University of Tx Md Anderson Can Ctr
- Study coordinator: Xiao, Yi
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.